Caris Partners with Everlywell on MCED Blood Test

Caris Life Sciences has entered a partnership with Everlywell to launch Caris Detect, its upcoming multi-cancer early detection blood test. The collaboration brings together Caris’ genomics and AI-driven precision medicine work with Everlywell’s digital health platform, which focuses on turning biomarker data into usable health insights.

Caris Detect is designed as a blood-based screening assay aimed at identifying multiple cancer types at an early stage. The test relies on whole genome sequencing to read molecular signals circulating in the bloodstream. These signals are then analyzed to detect patterns associated with different cancers, using Caris’ sequencing depth and analytical capabilities.

Through this partnership, Caris Detect will be made available via Everlywell’s platform. The goal is to combine cutting-edge cancer detection technology with the digital health infrastructure of the consumer-facing part that already handles testing, results delivery, and user engagement.

Also Read: A.D.A.M. Innovations Reveals the New ALUNAÉ Platform

Caris Life Sciences sees itself as a TechBio company of the future with patients as the center of attention and AI and next-gen sequencing as the main drivers in oncology. Everlywell utilizes its proven track record in digital diagnostics and biomarker intelligence. The consortium’s primary objective is to bring multi-cancer screening more towards the clinical and consumer side, delivering a blood test that is based on early signal detection instead of symptom-driven diagnosis.